Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE
BVF PARTNERS L P/IL reported a 5.90% stake in Monte Rosa Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2025 · Filed Feb 17, 2026
BVF PARTNERS L P/IL reported a 5.90% stake in Monte Rosa Therapeutics, Inc., 3,835,886 shares, as a passive investor on Dec 31, 2025. Filed Feb 17, 2026 (Schedule 13G/A).
- Stake
- 5.90%
- Shares
- 3,835,886
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 10 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 3.10% | 2,050,405 |
| BVF I GP LLC | 3.10% | 2,050,405 |
| BIOTECHNOLOGY VALUE FUND II LP | 2.30% | 1,496,859 |
| BVF II GP LLC | 2.30% | 1,496,859 |
| Biotechnology Value Trading Fund OS LP | 0.40% | 232,097 |
| BVF Partners OS Ltd. | 0.40% | 232,097 |
| BVF GP HOLDINGS LLC | 5.40% | 3,547,264 |
| BVF PARTNERS L P/IL | 5.90% | 3,835,886 |
| BVF INC/IL | 5.90% | 3,835,886 |
| LAMPERT MARK N | 5.90% | 3,835,886 |
Source
Related
- Monte Rosa Therapeutics, Inc.
- Bvf Partners L P
- Monte Rosa Therapeutics, Inc. shareholders
- Schedule 13G/A · Bvf Partners L P · May 15, 2026
- Schedule 13G/A · Bvf Partners L P · May 15, 2025
- Schedule 13G · Bvf Partners L P · Jan 31, 2025
- Form 4 · Bowen Matthew · Oct 6, 2026
- Schedule 13G/A · Montanova Capital, LLC · Aug 14, 2026
- Schedule 13G · Vestal Point Capital, LP · Aug 14, 2026
- Form 4 · Warmuth Markus · Jul 17, 2026
- Form 4 · Champoux Jennifer · Jul 16, 2026